Today in Banking: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Banking.

Press releases published on October 25, 2026

Oct. 25, 2026

SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Honeywell Aerospace, Inc. (NASDAQ: HONA) — Investors Who Suffered Losses Are Encouraged to Contact the Firm.

Indeterminate GlobeNewswire

Oct. 25, 2026

Duolingo, Inc. (DUOL) Class Action Lawsuit: Investors Face December 7, 2026, Deadline - Kessler Topaz Meltzer & Check, LLP

Indeterminate GlobeNewswire

Oct. 25, 2026

SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against D-Wave Quantum Inc. (NASDAQ: QBTS) — Investors Who Suffered Losses Are Encouraged to Contact the Firm

Indeterminate GlobeNewswire

Oct. 25, 2026

J.B. Hunt Investor News: If You Have Suffered Losses in J.B. Hunt Transport Services, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Indeterminate GlobeNewswire

Oct. 25, 2026

Beneficient Investor News: If You Have Suffered Losses in Beneficient, You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Indeterminate GlobeNewswire

Oct. 25, 2026

Crypto News: Remittix Announces 300 Million RTX Burn at Launch as JPMorgan Brings Two Tokenized Funds to Solana, Building the Case for a $300 SOL Price Prediction

Indeterminate GlobeNewswire

Oct. 25, 2026

Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Indeterminate GlobeNewswire

Oct. 25, 2026

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Honeywell Aerospace Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HONA

Indeterminate GlobeNewswire

Oct. 25, 2026

Webull Corporation (BULL) Class Action Lawsuit: Investors Face December 7, 2026, Deadline - Kessler Topaz Meltzer & Check, LLP

Indeterminate GlobeNewswire

Oct. 25, 2026

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Coastal Financial Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - CCB

Indeterminate GlobeNewswire

Oct. 25, 2026

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Triller Group Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ILLR

Indeterminate GlobeNewswire

Oct. 25, 2026

XTIA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds XTI Aerospace Investors of Securities Class Action Lawsuit Deadline on October 27, 2026

Indeterminate GlobeNewswire

Oct. 25, 2026

Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer …

Indeterminate GlobeNewswire

Oct. 25, 2026

ذكاء يتجلّى بوضوح: LUXEED تدشّن حضورها العالمي برؤية جديدة للفخامة ومتعة القيادة من خلال الذكاء

Indeterminate GlobeNewswire

Oct. 25, 2026

KECERDASAN, TERCERAHKAN: LUXEED Resmi Debut di Panggung Global, Mendefinisikan Ulang Kemewahan dan Kenikmatan Berkendara melalui Teknologi Cerdas

Indeterminate GlobeNewswire

Oct. 25, 2026

INTELLIGENCE, ENLIGHTENED: LUXEED เปิดตัวสู่ตลาดโลก…

Indeterminate GlobeNewswire

Oct. 25, 2026

Beyond Live Streaming: Tango Gives Back by Supporting Cancer Detection in Ukraine

Indeterminate GlobeNewswire

Oct. 25, 2026

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Indeterminate GlobeNewswire

Oct. 25, 2026

BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und Chemotherapie

Indeterminate GlobeNewswire

Oct. 25, 2026

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

Indeterminate GlobeNewswire